Interval between use of tixagevimab/cilgavimab (Evusheld™) for pre-exposure prophylaxis and vaccination against COVID-19

The prevention of SARS-CoV-2 infection and complications related to COVID-19 depends above all on the use of barrier measures and vaccination. Passive immunity conferred by the administration of neutralizing antibodies against SARS-CoV-2, such as EvusheldMCis an additional tool that can be used to prevent infection and morbidity and mortality from COVID-19. EvusheldMC is an additional […]